A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.

Shin FukudoHiroto MiwaAtsushi NakajimaKen HarumaMasanori KosakoAyako NakagawaHiraku AkihoYusuke YamaguchiJeffrey M JohnstonMark CurrieYoshikazu Kinoshita

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2018)

This study suggests that a linaclotide dose of 0.5 mg is effective and safe for IBS-C patients in Japan.

Keyphrases

irritable bowel syndrome
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
patient reported